Dr. Erik P. Castle spoke at the 23rd annual Perspectives in Urology Point • Counterpoint meeting on Saturday, November 15, 2014 on “BCG Immunotherapy: What’s New? ”.
Presentation
Keywords: Bacillus Calmette-Guérin (BCG), bladder cancer, immune therapy, cytology, lymphocytes, Th1, Th2
How to cite: Castle, Erik P. “BCG Immunotherapy: What’s New?” Grand Rounds in Urology. November 15, 2014. Accessed Nov 2024. https://dev.grandroundsinurology.com/bladder-cancer-erik-p-castle-bcg-immunotherapy/.
ABOUT THE AUTHOR
Dr. Erik P. Castle is a Professor of Urology at the Mayo Clinic College of Medicine. His surgical expertise includes minimally invasive urologic oncology, including robot-assisted radical cystectomy, prostatectomy, retroperitoneal lymph node dissection, and partial nephrectomy. He has demonstrated many of these procedures internationally, as he pioneered robot cystectomy as well as robot RPLND. He directs the International Laparoscopic Nephrectomy Program in Mexico on behalf of the American Urologic Association (AUA), and also serves on several committees and guideline panels within the American Urologic Association. He is on the Early Detection of Prostate Cancer Panel for the National Comprehensive Cancer Network (NCCN) as well.
Dr. Castle’s research interests include prostate cancer, bladder cancer, and kidney cancer. He is the Director of the Desert Mountain Care Prostate Cancer Research Fund and is the principal investigator of his lab housed at the Mayo Clinic Collaborative Research Building. His basic science research is focused on novel secondary hormonal therapies of prostate cancer and apoptotic pathways related to manipulations of the androgen and estrogen receptors. He also directs the prospectively collected genitourinary biorepository at Mayo Clinic Arizona, which houses over 40,000 specimens.
